Annual Report of Dr. Agarwal's Eye Hospital Limited for the financial year 2025-26 is submitted

August 14, 2026 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Script Code: 526783 Sub: Annual Report of Dr. Agarwal’s Eye Hospital Limited (the ‘Company’) for the financial year 2025-26 and e-voting for the ensuing Annual General Meeting of the Members of the Company Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, (‘SEBI Listing Regulations’) as amended, we enclose herewith the Annual Report of the Company for the financial year 2025-26, along with the Notice convening the 32nd Annual General Meeting (AGM) of the Company scheduled to be held on Wednesday, September 09, 2026, at 10.30 A.M. (IST) through Video Conferencing/ Other Audio- Visual Means. The Annual Report of the Company for the financial year Notice of 32ndAGM of the Company 2025-26 along with the 32nd AGM Notice comprising the items of business proposed to be transacted thereat are also Annual Report of the Company for made available on the Company’s website via the given links: the Financial Year 2025-26 In terms of Section 108 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and the provisions of Regulation 44 of the SEBI Listing Regulations, the Company is providing its members with the facility to exercise their votes electronically to transact the business as set out in the Notice convening the 32nd Annual General Meeting of the Company. The Company has entered into an arrangement with Central Depository Services Ltd (CDSL) for facilitating e-voting through their e-voting platform i.e. https://www.evotingindia.com/. The electronic dispatch of annual reports to the members of the company has commenced today i.e., Friday, August 14, 2026. We request you to kindly take the above on record. For Dr. Agarwal’s Eye Hospital Limited Meenakshi Jayaraman Company Secretary and Compliance Officer Encl.: as above. 2025 - 2026 Corporate Overview Statutory Reports Financial Statements Annual Report 2025-26 1 CONTENTS Chairman’s Desk 03 Board of Directors 05 Financial Highlights 08 Notice to the Members 09 Directors’ Report 23 Management Discussions and Analysis Report 33 Corporate Governance Report 42 Independent Auditor’s Report 58 Balance Sheet as at March 31, 2026 68 Statement of Profit and Loss for the year ended March 31, 2026 70 Statement of Cash Flows for the year ended March 31, 2026 71 Statement of Changes in Equity for the year ended March 31, 2026 73 Notes Forming Part of the Financial Statements for the year ended 74 March 31, 2026 2 Dr. Agarwal’s Eye Hospital Limited CORPORATE INFORMATION CHAIRMAN’S DESK Building the Future of Eye Care Dear Shareholders, BOARD OF DIRECTORS Financial Year 2025-26 has been another defining year in our journey of transforming eye care. As we continue to pursue our purpose of making world-class ophthalmic care accessible to every patient, Dr. Amar Agarwal (DIN: 00435684) Chairman cum Managing Director our focus has remained unwavering—delivering clinical excellence, expanding our reach, embracing Dr. Athiya Agarwal (DIN: 01365659) Whole Time Director innovation, and creating long-term value for all our stakeholders. Dr. Adil Agarwal (DIN: 01074272) Non-Executive Director Redefining Clinical Excellence CA Balakrishnan Venkatraman (DIN: 02825465) Independent Director Mrs. Latha Ramanathan (DIN: 07099052) Independent Director At Dr. Agarwal's, innovation has always been at the heart of our identity. This year, we witnessed a landmark moment in ophthalmology with the growing adoption of Pinhole Pupilloplasty (PPP)—a Mr. Shiv Agrawal (DIN: 00040199) Independent Director pioneering procedure developed at Dr. Agarwal’s. PPP represents a significant breakthrough in the treatment of complex corneal disorders by offering patients a viable alternative to corneal CHIEF FINANCIAL OFFICER transplantation. By eliminating the dependence on scarce donor corneas while delivering predictable Mr. Yashwanth Venkat and remarkable visual outcomes, this innovation has the potential to redefine the standard of care for thousands of patients across the world. Much like how coronary stents transformed the COMPANY SECRETARY & COMPLIANCE OFFICER treatment of heart disease by reducing reliance on bypass surgery, PPP has the potential to redefine Ms. Meenakshi Jayaraman the future of corneal rehabilitation.It exemplifies our commitment not only to delivering exceptional care but also to shaping the future of ophthalmology through indigenous clinical innovation. AUDITORS S. R. Batliboi & Associates LLP Building Scale Through Organic Growth Chartered Accountants Our organic growth strategy continues to demonstrate its strength as one of the key pillars of our ICAI Firm Registration No. 101049W/E300004 long-term expansion. Over the years, we have developed a disciplined and repeatable playbook for 10th Floor, Tidel Park, "A" Block, North Wing, launching and scaling greenfield centres, enabling faster ramp-up, improved operating leverage, and No.4, Rajiv Gandhi Salai, Taramani, Chennai - 600 113 stronger profitability with every successive expansion cycle. Most importantly, our mature centres are now generating the cash flows needed to fund our next phase of growthcreating a self-sustaining BANKERS TO THE COMPANY model that allows us to expand without compromising financial discipline. Axis Bank, Anna Nagar, Chennai. Our focus remains on deepening our presence across Tamil Nadu, where Dr. Agarwal Eye Hospital has REGISTERED OFFICE built a strong legacy and established brand equity. We continue to selectively expand our network across underserved markets, while strengthening our existing centres through investments in clinical 6th Floor, Menon Eternity, 1st Main Road, capabilities, medical talent and advanced ophthalmic technology. This approach will enable us to Austin Nagar, Alwarpet, deepen our presence in the state, improve access to quality eye care and drive sustainable long-term Chennai, Tamil Nadu, 600018 growth. Website: www.dragarwal.com CIN: L85110TN1994PLC027366 Creating a Stronger, Integrated Platform Telephone: 91-044-43787777, Email: investor@dragarwal.com A defining milestone this year was the shareholders’ approval for the merger of Dr. Agarwal's Eye Hospital Limited with. The merger creates a simpler, more integrated organization, enabling faster REGISTRAR & SHARE TRANSFER AGENT decision-making, greater operational efficiency, and seamless deployment of talent and capital Integrated Registry Management Services Private Limited. across our network. It also strengthens our financial position through improved capital allocation and 2nd floor, Kences Towers, a more efficient balance sheet, while creating a cleaner, more transparent corporate structure that No.1 Ramakrishna Street, North Usman Road, supports our long-term growth ambitions. T Nagar, Chennai - 600 017 Tel - 044 2814 0801-03, Email: einward@integratedindia.in Corporate Overview Statutory Reports Financial Statements Annual Report 2025-26 3 CORPORATE INFORMATION CHAIRMAN’S DESK Building the Future of Eye Care Dear Shareholders, BOARD OF DIRECTORS Financial Year 2025-26 has been another defining year in our journey of transforming eye care. As we continue to pursue our purpose of making world-class ophthalmic care accessible to every patient, Dr. Amar Agarwal (DIN: 00435684) Chairman cum Managing Director our focus has remained unwavering—delivering clinical excellence, expanding our reach, embracing Dr. Athiya Agarwal (DIN: 01365659) Whole Time Director innovation, and creating long-term value for all our stakeholders. Dr. Adil Agarwal (DIN: 01074272) Non-Executive Director Redefining Clinical Excellence CA Balakrishnan Venkatraman (DIN: 02825465) Independent Director Mrs. Latha Ramanathan (DIN: 07099052) Independent Director At Dr. Agarwal's, innovation has always been at the heart of our identity. This year, we witnessed a landmark [Showing first 8,000 characters — download PDF for full document]